LONDON — British regulators have become the first to authorize the COVID-19 vaccine developed by American drugmaker Pfizer and Germany's BioNTech for emergency use. Because trials of the vaccine have shown it has 95% efficacy, there is acute interest in how the U.K. plans to implement potentially its biggest-ever immunization program. Here's a look at what is known about Britain's vaccination plan:
___
HOW MUCH OF THE VACCINE DOES THE U.K. HAVE?
Not enough. The U.K. has put in orders for 40 million doses, which can inoculate 20 million people, since each person gets two doses 21 days apart. Other vaccines will be needed for all the 53 million or so people eligible for shots; the U.K. only plans to immunize the population over age 16.
___
WHEN WILL THE ROLLOUT BEGIN?
The plan is to start a phased rollout of the Pfizer/BioNTech vaccine early next week across the U.K., including from 50 "hospital hubs" in England. Around 800,000 doses are slated to arrive from Belgium in the coming days. The aim is for the bulk of the first deliveries to be used on the most "at-risk" groups — nursing home residents and their caregivers, as well as people over age 80. The National Health Service will take the lead in the rollout of the vaccine, which eventually will expand to pharmacies and specially built vaccination centers.
___